Pilot of Continuous Glucose Monitor-Augmented Food Is Medicine
Launched by UNIVERSITY OF NORTH CAROLINA, CHAPEL HILL ·
Trial Information
Current as of September 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new approach to help adults with type 2 diabetes who also face challenges with nutrition or access to healthy food. The study is looking at whether using a continuous glucose monitor (CGM)—a small device that tracks blood sugar levels in real time—along with nutrition counseling can better support healthy eating and blood sugar control compared to just receiving healthy food support alone.
Adults aged 65 to 74 with type 2 diabetes may be eligible to join. Participants will be randomly assigned to one of two groups for 16 weeks. For the first 12 weeks, one group will receive the food program plus the glucose monitor and counseling, while the other group will receive the food program without the monitor or counseling. In the final 4 weeks, everyone will get both the food program and the glucose monitor to use on their own. Some participants will also be invited to share their experiences in interviews to help improve the program for more people in the future. This study aims to find out if combining real-time blood sugar tracking with food support can make managing diabetes easier and more effective.
Gender
ALL
Eligibility criteria
About University Of North Carolina, Chapel Hill
The University of North Carolina at Chapel Hill (UNC) is a leading research institution renowned for its commitment to advancing health and science through innovative clinical trials. With a robust infrastructure that supports multidisciplinary collaboration, UNC conducts cutting-edge research across various fields, including medicine, public health, and biomedical sciences. The university is dedicated to improving patient care and health outcomes by translating its research findings into practical applications. UNC’s clinical trials are designed to evaluate new therapies, interventions, and technologies, ensuring that they meet the highest ethical and scientific standards while fostering a culture of inclusivity and community engagement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anna Kahkoska, MD, PhD
Principal Investigator
University of North Carolina, Chapel Hill
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported